Condition

Primary Myelofibrosis clinical trials and research

• 23Clinical trials
• 2NIH research projects
• 23Countries

Newest Primary Myelofibrosis clinical trials

All recruiting trials (23)

• MPN PROGRESSion Registry — tracking symptoms, treatments, and disease progression in people with MPNs.

  Track long-term symptoms, treatments, and disease progression in adults with myeloproliferative neoplasms to see how these conditions evolve over time.

  Recruiting at 2 sites MPN Research Foundation · Chicago, Illinois and 1 other locations · NCT07362225

• Ruxolitinib given before, during, and after donor stem cell transplant for older adults with myelofibrosis or MDS/MPN overlap

  This phase II test tries whether giving ruxolitinib before, during, and after an allogeneic stem cell transplant helps older adults with myelofibrosis or MDS/MPN overlap have better transplant outcomes and fewer complications like graft-versus-host disease.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT07228624

• National registry for people with myelofibrosis and anemia in Germany.

  This project will collect health, treatment, and quality-of-life information from people in Germany with primary or secondary myelofibrosis and anemia to see how their care and symptoms change over time.

  Recruiting iOMEDICO AG · Multiple Locations · NCT06976918

• Investigating the effects of mesenchymal stromal cell vesicles on blood cell development in myelofibrosis patients

  This study is testing how special cells from patients with myelofibrosis affect the growth of blood cells to see if they behave differently than those from healthy people.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia, Pavia · NCT06896344

• Comparing ASTX727 with and without Iadademstat for advanced blood cancers

  This study is testing whether adding iadademstat to the ASTX727 treatment can help people with advanced blood cancers feel better and live longer compared to just using ASTX727 alone.

  Recruiting at 32 sites Phase 2 National Cancer Institute (NCI) · Irvine, California and 31 other locations · NCT06661915

• Combining Momelotinib and Luspatercept for Myelofibrosis Treatment

  This study is testing if combining two medications, momelotinib and luspatercept, can help people with myelofibrosis who need blood transfusions feel better and reduce their transfusion needs.

  Recruiting at 33 sites Phase 2 GlaxoSmithKline · Ann Arbor, Michigan and 32 other locations · NCT06517875

• Combining Momelotinib and Luspatercept for Myelofibrosis Treatment

  This study is testing if combining two medications, momelotinib and luspatercept, can help people with myelofibrosis who need blood transfusions feel better and reduce their transfusion needs.

  Recruiting at 33 sites Phase 2 GlaxoSmithKline · Ann Arbor, Michigan and 32 other locations · NCT06517875

• Observational study on ruxolitinib for myelofibrosis patients

  This study looks at how well ruxolitinib works for people with myelofibrosis and how different factors affect their long-term survival.

  Recruiting at 26 sites IRCCS Azienda Ospedaliero-Universitaria di Bologna · Cosenza, Calabria and 25 other locations · NCT06516406

• Adding navtemadlin to ruxolitinib for myelofibrosis patients with poor response

  This study is testing if adding a new drug called navtemadlin to ruxolitinib can help myelofibrosis patients who aren't doing well on ruxolitinib alone.

  Recruiting at 214 sites Phase 3 Kartos Therapeutics, Inc. · Birmingham, Alabama and 214 other locations · NCT06479135

• Characterizing Monocytes in Blood Disorders

  This study is trying to learn more about the role of certain blood cells called monocytes in patients with specific blood disorders to see how they might affect the disease and treatment options.

  Recruiting University Hospital, Angers · Angers, Maine et Loire and 2 other locations · NCT06361641

• Evaluating the safety and effectiveness of bomedemstat for blood disorders

  This study is trying to see how safe and effective bomedemstat is for people with blood disorders like essential thrombocythemia and myelofibrosis who have been doing well on the treatment for at least six months.

  Recruiting at 18 sites Phase 3 Merck Sharp & Dohme LLC · Ann Arbor, Michigan and 20 other locations · NCT06351631

• Testing a new drug for patients with myelofibrosis who didn't respond to previous treatments

  This study is testing a new drug for people with myelofibrosis who haven't had success with previous treatments to see if it’s safe and effective.

  Recruiting at 17 sites Phase 1 Eli Lilly and Company · Palo Alto, California and 20 other locations · NCT06343805

• Evaluating tasquinimod for treating myelofibrosis

  This study is testing if tasquinimod, alone or with another drug called ruxolitinib, can help people with myelofibrosis feel better and slow down their disease.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT06327100

• Combining Pacritinib and Talazoparib for Patients with Myeloproliferative Neoplasms Not Responding to JAK2 Therapy

  This study is testing a combination of two medications, pacritinib and talazoparib, to see if they can help patients with certain blood cancers who haven't responded to other treatments.

  Recruiting Phase 1 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT06218628

• Using 68Ga-FAPI PET/CT imaging to diagnose and evaluate myelofibrosis.

  This study is testing a new imaging method using 68Ga-FAPI PET/CT to see if it can better diagnose myelofibrosis compared to regular CT scans.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06151119

• Assessing the safety of fedratinib in Korean patients with myelofibrosis

  This study is testing the safety of a drug called fedratinib in adults with myelofibrosis who haven't responded well to or can't tolerate another treatment called ruxolitinib.

  Recruiting at 2 sites Bristol-Myers Squibb · Seoul and 2 other locations · NCT06073847

• Infusion of selected stem cells to improve graft function in blood cancer patients

  This study is testing if infusing special stem cells can help blood cancer patients who have had problems with their stem cell transplant feel better and avoid complications.

  Recruiting Phase 1 University of Alabama at Birmingham · Birmingham, Alabama · NCT06047886

• Registry of Asian patients with myeloproliferative neoplasms

  This study is collecting information from Asian patients with myeloproliferative neoplasms to learn more about their condition and how different treatments work for them.

  Recruiting The University of Hong Kong · Hong Kong · NCT05882773

• Evaluating DISC-0974 for treating anemia in myelofibrosis patients

  This study tests if a new treatment called DISC-0974 can help people with myelofibrosis who have anemia feel better and improve their condition.

  Recruiting at 33 sites Phase 1/2 Disc Medicine, Inc · Gilbert, Arizona and 34 other locations · NCT05320198

• Combining TL-895 with Ruxolitinib for treating Myelofibrosis

  This study is testing if combining TL-895 with Ruxolitinib can help people with Myelofibrosis feel better, especially those who haven't responded well to Ruxolitinib alone.

  Recruiting at 19 sites Phase 1/2 Telios Pharma, Inc. · Birmingham, Alabama and 18 other locations · NCT05280509

• Using a JAK inhibitor before and after haploidentical transplantation for myelofibrosis treatment

  This study is testing if a JAK inhibitor can help people with myelofibrosis have a better outcome after a specific type of stem cell transplant by preventing complications and promoting successful recovery.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT04370301

• Combining decitabine with ruxolitinib, fedratinib, or pacritinib for treating advanced myeloproliferative neoplasms

  This study is testing if combining decitabine with other medications can help patients with advanced blood cancers get ready for a stem cell transplant.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT04282187

• Registry for patients with myeloproliferative neoplasms

  This study is creating a database to gather information from people with myeloproliferative neoplasms to help improve treatments and outcomes for these rare blood cancers.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT02760238

NIH-funded research (2)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Megakaryocyte changes in myelofibrosis and its progression to leukemia

  A scientist-guided project will study how abnormal megakaryocytes and signals like TGF-β and IL-13 may drive progression from myelofibrosis toward acute leukemia, with potential implications for future treatments.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-11399019

• How abnormal platelet‑making cells drive worsening primary myelofibrosis

  Looks at whether changes in megakaryocytes (the cells that make platelets) and the signals they release make primary myelofibrosis worse for people with the disease.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-11094801

Related topics

Quick answers

How many Primary Myelofibrosis clinical trials are recruiting right now?

23, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 23 countries. The most sites are in United States (15 trials), Italy (8 trials), France (6 trials), Spain (5 trials), Germany (5 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 6, Phase 1/2: 3, Phase 1: 3, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →